Loading...
NPI 1043309735 · Orlando, FL · Specialty Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Accredo Health Group Inc is a specialty pharmacy provider located in Orlando, Florida. This profile covers 1 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Accredo Health Group Inc |
| Address | 6272 Lee Vista Blvd |
| City | Orlando |
| State | FL |
| ZIP | 32822 |
| Taxonomy | Specialty Pharmacy |
| NPI Enumerated | October 12, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $18.1M |
| Medicare | $10.5K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0068 | Professional services for the administration of anti-infective, pain management, chelation, pulmonary hypertension, inotropic, or other intravenous infusion drug or biological (excluding chemotherapy… | 460 | $20 | $10.5K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0068 | 1 | 10 | 460 | $20 | $10.5K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2326 | Injection, nusinersen, 0.1 mg | 130 | $130,650 | $16.5M |
| J1325 | Injection, epoprostenol, 0.5 mg | 2,680 | $380 | $1M |
| J3285 | Injection, treprostinil, 1 mg | 180 | $1,730 | $302.2K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 90 | $1,230 | $110.7K |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | 3,160 | $40 | $110.5K |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | 4,180 | $10 | $29.2K |
| K0455 | Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol) | 990 | $10 | $13.8K |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 40 | $20 | $530 |
| K0552 | Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each | 720 | $0 | $0 |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | 180 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J2326 | Injection, nusinersen, 0.1 mg | 1 | 10 | 130 | $130,650 | $16.5M |
| J1325 | Injection, epoprostenol, 0.5 mg | 1 | 10 | 2,680 | $380 | $1M |
| J3285 | Injection, treprostinil, 1 mg | 1 | 10 | 180 | $1,730 | $302.3K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 12 | 20 | 80 | $430 | $124.8K |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | 1 | 10 | 740 | $40 | $40.7K |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 16 | 20 | 810 | $1 | $22.3K |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | 2 | 10 | 260 | $20 | $21.5K |
| K0552 | Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each | 2 | 10 | 1,020 | $20 | $18.4K |
| K0455 | Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol) | 1 | 10 | 990 | $10 | $13.3K |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | 17 | 20 | 820 | $1 | $560 |
Other providers in the same ZIP code as Accredo Health Group Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Children's Home Society Of Florida | FL | Community/Behavioral Health Agency | $0 | $29.4M |
| The Devereux Foundation | FL | Community Health Clinic/Center | $0 | $29.2M |
| Professional Psychiatric Services, LLC | FL | Community/Behavioral Health Agency | $0 | $8.2M |
| Compassion Pediatrics LLC | FL | Pediatrics Physician | $0 | $8M |
| First 2 Aid Ems, Inc | FL | Land Ambulance | $665.4K | $418.8K |
| Benyam Yoseph | FL | General Practice Physician | $738.5K | $0 |
| Christopher Smith | FL | Internal Medicine Physician | $732.1K | $0 |
| Fyzamedical LLC | FL | Clinical Medical Laboratory | $457.4K | $8.5K |
| Michael Hawks | FL | Orthopaedic Surgery Physician | $215.5K | $0 |
| Edwin Martinez Mejias | FL | Cardiovascular Disease Physician | $131.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.